Membranous Nephropathy
Conditions
Keywords
TW, Valsartan, treatment, membranous nephropathy, proteinuria
Brief summary
The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment of heavy proteinuria of membranous nephropathy.
Detailed description
Membranous nephropathy with heavy proteinuria have high risks of progressing to CRF. Tripterygium (TW) is a Chinese traditional patent drugs, it can reduce proteinuria of chronic glomerular nephritis,such as IgA nephropathy. So, we designed this randomized, prospective clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of heavy proteinuria of MN.
Interventions
DRUGTW
TW,120mg/d
Sponsors
Nanjing University School of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Biopsy-proven idiopathic membranous nephropathy * Nephrotic syndrome with proteinuria (\> 4 g/day) and serum albumin \< 30 g/dl * Age over 18 with informed consent
Exclusion criteria
* Patient with abnormal liver function tests * Prior therapy with sirolimus, CSA, MMF, tacrolimus or azathioprin, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days, * Active/serious infection, * Patient with hepatitis B surface antigen or who is hepatitis C antibody positive
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of membranous nephropathy | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| To investigate the safety and tolerability of TW vs ARB in treatment of MN | 12 months |
Countries
China
Outcome results
None listed